Mucinous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with first-line oxaliplatin- and/or irinotecan-based chemotherapy

Catalano, Vincenzo; Loupakis, Fotios; Graziano, Francesco; Torresi, U.; Bisonni, Renato; Mari, D.; Fornaro, Lorenzo; Baldelli, Anna Maria; Giordani, Paolo; Rossi, David; Alessandroni, Paolo; Giustini, Lucio; Silva, R. R.; Falcone, Alfredo; Demidio, S.; Fedeli, Sara

doi:10.1038/sj.bjc.6604955

Cited by 175 publications

(158 citation statements)

References 31 publications

(46 reference statements)

Supporting

Mentioning

136

Contrasting

Unclassified

Order By: Relevance

“…Several studies reported that patients with colorectal mucinous adenocarcinoma had a poorer prognosis compared with that of patients with non-mucinous adenocarcinoma (57)(58)(59). Differences in metastatic patterns between histological subtypes of colorectal cancer and a high number of peritoneal metastases in colorectal mucinous adenocarcinomas have also been reported (60)(61)(62)(63). However, the underlying mechanisms for the differences in metastatic patterns between various histological subtypes remain unclear.…”

Section: Discussionmentioning

confidence: 95%

Nuclear expression of claudin‑3 in human colorectal adenocarcinoma cell lines and tissues

et al. 2017

View full text Add to dashboard Cite

Abstract.Claudins are members of a large family of transmembrane proteins, which are essential for the formation of tight junctions and have a significant effect on the biological behavior of tumor progression. Previous studies have demonstrated that several claudins show aberrant expression patterns in numerous types of cancer. The present study investigated the expression and localization of claudin-3 and claudin-7 in human colorectal adenocarcinoma cell lines and tissues. The protein expression levels of claudin-3 and claudin-7 were determined using immunocytochemical and immunohistochemical staining. Claudin-3, but not claudin-7, exhibited nuclear localization in the human colorectal adenocarcinoma Caco-2 and SW620 cell lines. Surgically resected colorectal adenocarcinoma tissue specimens were obtained, and the associations between the expression of claudin-3 or claudin-7 and various clinicopathological parameters were analyzed. The membranous expression rates of claudin-3 and claudin-7 were 58.0 and 50.0%, while their nuclear expression rates were 22.0 and 2.0%, respectively. The membranous expression of claudin-3 and claudin-7 was not associated with any clinicopathological factors, whereas the nuclear expression of claudin-3 was associated with histological type and was significantly increased in colorectal mucinous adenocarcinomas compared with that in well-to moderately-differentiated colorectal adenocarcinomas (P<0.01). However, no associations were observed between the nuclear expression of claudin-7 and any clinicopathological parameter. In conclusion, the nuclear expression of claudin-3 in colorectal mucinous adenocarcinoma may be involved in the biological transformation of tumors. The results from the present study indicated that claudin-3 is an important protein associated with histological type and has potential as a prognostic marker. Although the mechanisms underlying the nuclear localization of claudin-3 in tumorigenesis have not yet been elucidated in detail, the present results indicated the potential of claudin-3 as a histopathological biomarker for colorectal adenocarcinomas.

show abstract

Section: Discussionmentioning

confidence: 95%

Nuclear expression of claudin‑3 in human colorectal adenocarcinoma cell lines and tissues

et al. 2017

View full text Add to dashboard Cite

show abstract

“…There are 3759 English literatures in original search, after exclusion and screening, 28 English literatures (Cusack et al, 1996;Sun et al, 1996;Wu et al, 1996;Enriquez et al, 1998;Cerottini et al, 1999;Consorti et al, 2000;Nozoe et al, 2000;Kanemitsu et al, 2003;Chen et al, 2004;Du et al, 2004;Papadopoulos et al, 2004;Kang et al, 2005;You et al, 2006;Grillo-Ruggieri et al, 2007;Hill et al, 2007;Lee et al, 2007;Farhat et al, 2008;Pande et al, 2008;Catalano et al, 2009;Min et al, 2009;Song et al, 2009;Xie et al, 2009;Sultan et al, 2010;Catalano et al, 2011;Jivapaisarnpong et al, 2011;Hyngstrom et al, 2012;Langner et al, 2012;Yamaguchi et al, 2012) and 2 Chinese literatures (Songqing et al, 2002;Miao et al, 2005) meet the requirements. In the 30 literatures, 21 literatures can be used for Meta analysis of the relationship of mucinous adenocarcinoma and TNM staging, including 444489 cases, in which mucinous adenocarcinoma were 45050 cases, accounting for 10.1% of all cases; 21 literatures can be used for Meta analysis of relationship of mucinous adenocarcinoma and prognosis, including 450804 cases, in which mucinous adenocarcinoma were 45354 cases, accounting for 10.1% of all cases.…”

Section: The General Results Of Selected Literaturementioning

confidence: 99%

“…Yamaguchi et al (2012) also supported this result. However, some other findings showed that mucinous adenocarcinoma was an independent prognostic risk factor (Kanemitsu et al, 2003;Catalano et al, 2009;Ghabeljoo et al, 2011). Some studies showed that mucinous adenocarcinoma might reduce the sensitivity of radiotherapy and chemotherapy in recent years (Negri et al, 2005;Sengul et al, 2006).…”

Section: Introductionmentioning

confidence: 99%

TNM Stages and Prognostic Features of Colorectal and Mucinous Adenocarcinoma Patients: a Meta Analysis

Chen¹,

Tang²,

Xiang³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Aim: The significance of the mucinous adenocarcinoma in TNM staging and prognosis for colorectal tumor patients is still controversial. The aim was to provide a meta-analysis for TNM staging and prognostic features of colorectal tumors. Methods: 30 individual case-control studies were finally included into this meta-analysis, involving a total of 444,489 cancer cases and 45,050 mucinous adenocarcinomas, of relations with TNM staging and prognostic features. Results: Compared to non-mucinous adenocarcinoma patients, the TNM IV stage accounted for a larger percentage of mucinous adenocarcinomas (OR=1.48, 95%CI 1.28-1.71, POR<0.001) and the prognosis was significantly poor (HR=1.06, 95%CI 1.04-1.08, P<0.001). After heterogeneity testing, the results was similar to the holistic approach outcome (HR=1.48, 95%CI 1.35-1.62, P<0.001). Conclusion: Compared to patients with non-mucinous adenocarcinomas, mucinous adenocarcinoma patients with later TNM staging make up a big percentage, and mucinous adenocarcinoma is an independent risk factor for poor prognosis.

show abstract

“…In that study, patients with CRC had a lower response rate to 5-FU (22% versus 47%) and shorter survival time (11.8 Mucinous Adenocarcinomas months versus 17.9 months) than patients with nonmucinous CRC. Moreover, Catalano et al [54] reported, in patients with mucinous CRC treated with irinotecan and/or oxaliplatin-based chemotherapy, a significantly lower response rate and overall survival time than in patients with nonmucinous CRC (18.4% versus 49% and 14 months versus 23.4 months, respectively). Currently, no studies focusing on outcome for different molecular subtypes of MCA with metastatic disease confined to the peritoneum are available.…”

Section: Mcamentioning

confidence: 99%

Mucinous Adenocarcinomas with Intra-Abdominal Dissemination: A Review of Current Therapy

Winder

Lenz

2010

The Oncologist

View full text Add to dashboard Cite

Peritoneal carcinomatosis has been considered a terminal disease with a median survival time of 5.2-12.6 months. Systemic chemotherapy and cytoreductive surgery (CRS) have long been used to treat macroscopic disease, with limited success. However, a comprehensive treatment approach involving cytroreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) has evolved into a novel approach for peritoneal carcinomatosis. Surgery removes the primary cancer and any dissemination within the peritoneal cavity and adjuvant HIPEC eradicates macroscopic or microscopic tumor residue, thus reducing the risk for recurrence. This approach offers a new potential treatment option for patients with metastatic disease confined to the peritoneum. The present review provides an update of the most recent data on the current therapy for pseudomyxoma peritonei (PMP) and mucinous colorectal adenocarcinoma (MCA) with metastatic disease confined to the peritoneum. The Oncologist 2010;15:836 -844

show abstract

Mucinous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with first-line oxaliplatin- and/or irinotecan-based chemotherapy

Cited by 175 publications

References 31 publications

Nuclear expression of claudin‑3 in human colorectal adenocarcinoma cell lines and tissues

Nuclear expression of claudin‑3 in human colorectal adenocarcinoma cell lines and tissues

TNM Stages and Prognostic Features of Colorectal and Mucinous Adenocarcinoma Patients: a Meta Analysis

Mucinous Adenocarcinomas with Intra-Abdominal Dissemination: A Review of Current Therapy

Contact Info

Product

Resources

About